GlassScriptPhysician profile
Lenore R Chiles
NPI 1487614459
$1,062.28
in general payments reported to CMS, 2019-2025
16 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $132 · 2021: $108 · 2022: $197 · 2023: $42.55 · 2024: $196 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $267.09 | 2019-2024 | |
| Leo Pharma INC. | $168.26 | 2024-2025 | Adbry, Anzupgo |
| Allergan, INC. | $113.12 | 2020 | |
| Pfizer INC. | $88.05 | 2019 | |
| Sun Pharmaceutical Industries INC. | $78.41 | 2025 | |
| Janssen Biotech, INC. | $76.39 | 2021-2022 | |
| Amgen INC. | $72.73 | 2024-2025 | Otezla, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Organon LLC | $25.71 | 2024-2025 | |
| Kerecis Limited | $23.82 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Ucb, INC. | $21.83 | 2024 | Bimzelx |
| Genzyme Corporation | $20.35 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.12 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.52 | 2023 | Sotyktu |
| Lilly USA, LLC | $19.27 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $16.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lenore Chiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.